Epkinly — Net revenues
Products & Services · Net revenuesAbbVie Epkinly — Net revenues increased by 17.4% to $81.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 102.5%, from $40.00M to $81.00M. Over 2 years (FY 2023 to FY 2025), Epkinly — Net revenues shows an upward trend with a 195.7% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates successful market adoption, expanded clinical indications, or improved patient access for the therapy, while a decrease may signal increased competition, patent expirations, or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total net sales generated from the commercialization of a specific oncology therapeutic produ...
Peer comparison
Comparable to specific product revenue lines reported by other large-cap biopharmaceutical companies, particularly those focused on specialty oncology or immunology franchises.
abbv_segment_epkinly_net_revenuesHistorical Data
| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $14.00M | $17.00M | $27.00M | $36.00M | $43.00M | $40.00M | $51.00M | $70.00M | $69.00M | $81.00M |
| QoQ Change | — | — | — | +21.4% | +58.8% | +33.3% | +19.4% | -7.0% | +27.5% | +37.3% | -1.4% | +17.4% |
| YoY Change | — | — | — | — | — | — | +207.1% | +135.3% | +88.9% | +94.4% | +60.5% | +102.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is AbbVie's epkinly — net revenues?
- AbbVie (ABBV) reported epkinly — net revenues of $81.00M in Q4 2025.
- How has AbbVie's epkinly — net revenues changed year-over-year?
- AbbVie's epkinly — net revenues increased by 102.5% year-over-year, from $40.00M to $81.00M.
- What is the long-term trend for AbbVie's epkinly — net revenues?
- Over 2 years (2023 to 2025), AbbVie's epkinly — net revenues has grown at a 195.7% compound annual growth rate (CAGR), from $31.00M to $271.00M.
- What does epkinly — net revenues mean?
- The total net sales revenue generated by the specific oncology drug product line.